Carolinas HealthCare System
Neuroscience Locations

Neuroscience Clinical Trials

Current Alzheimer's Disease (AD) enrolling studies with a brief description:

Study and Contact Information

EnVivo (sponsored by Forum Pharmaceuticals)

Protocol #: EVP-6124-025A

Principal Investigator: Oleg V. Tcheremissine, MD

Coordinators: Dineen Gardner – 704-446-7511 & Megan Kramer – 704-446-0803


This study is being done for the investigational drug, EVP-6124 or encenicline. “Investigational” means the drug is not approved for sale by the U.S. Food and Drug Administration or any other regulatory or health agency.
The EnVivo study aims to determine if EVP-6124 is a safe and effective treatment for Alzheimer’s disease. EVP-6124 targets certain areas in the brain that contain receptors that are important for cognitive and memory functions.

The study is being conducted at 60-80 centers worldwide, including CMC-Neurology. Approximately 790 people will participate for up to 34 weeks (238 days). There will be at least 10 visits to the study site as well as contacts by phone. Subjects who complete this study may have the option to participate in a separate study during which they would receive EVP-6124 for an additional 26 weeks (182 days). Individuals who do not participate in the extension study will be contacted by phone 30 days after the last time they took the study drug.

Current Amyotrophic Lateral Sclerosis (ALS) enrolling studies with a brief description:

Study and Contact Information

Ibudilast in ALS (sponsored by MediciNova Inc.)

Protocol #: MN-166-ALS-1201

Principal Investigator: Benjamin Brooks, MD

Coordinator: Cynthia Lary – 704-446-6063


The primary goal of this study is to evaluate the safety, tolerability and effectiveness of the investigational drug ibudilast when administered as an adjunct to riluzole in people with ALS.
Sixty subjects from 18 to 80 years old will be enrolled. Participants will be randomized (like flipping a coin) into 1 of 2 groups: group 1 will receive ibudilast with riluzole; group 2 will receive placebo (which looks like the ibudilast tablet, but has no active ingredients) with riluzole. This part of the study is called “double blind,” because neither the study staff nor the study patients will know which group the participants are in.

After completing the double-blind phase, subjects randomized to the placebo arm will begin to receive ibudilast for an additional 6 months so that researchers can further evaluate the drug’s safety and tolerability. If researchers find no concerns, they will decide whether to extend participation to the ibudilast-treated group for an additional six months.

DPS (sponsored by MDA and ALSA)

Protocol #: HUD #10-0242

Principal Investigator: Benjamin Brooks, MD

Coordinator: Cynthia Lary – 704-446-6063


This study is being done to find out if the NeuRx® Diaphragm Pacing System™ (DPS) will improve breathing function or prolong life span in people with ALS. The study also aims to compare measures of diaphragm function, dyspnea and quality of life between the standard of care group and DPS group.

Study participants must be at least 21. They will be randomized into one of two groups. One group (two-thirds of participants) will receive the DPS and the other group (one-third of participants) will receive standard medical care for ALS. Participants receiving standard medical care will be the “control” group in order to tell whether the effects seen are truly from the DPS.

Exercise (sponsored by Johns Hopkins University)

Protocol #: NA_00022650

Principal Investigator: Benjamin Brooks, MD

Coordinator: Cynthia Lary – 704-446-6063

The purpose of this study is to see whether one type of exercise is tolerated better and is safer than another for people with ALS. Researchers also will collect information about how the body responds to exercise in people with ALS.

In this study, participants exercise in one of three ways: 1) weightlifting (resistance exercise); 2) stationary bicycling (endurance exercise), and 3) range of motion/stretching exercise (the “standard of care” for ALS patients). If resistance, endurance or range of motion exercise is shown to be well-tolerated and safe over 24 weeks, a larger trial will be planned to determine if exercise is beneficial to ALS patients.

MDA Patient Registry (sponsored by MDA)

Protocol #: None

Principal Investigator: Benjamin Brooks, MD

Coordinator: Janice Rucker – 704-446-1902

This is a study for children and adults who have been diagnosed with amyotrophic lateral sclerosis (ALS), Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD) or spinal muscular atrophy (SMA). The study is an ongoing data collection effort known as the Patient Registry and sponsored by the Muscular Dystrophy Association (MDA). The Patient Registry collects data – via several questionnaires based on previous clinical assessments and patients’ own responses – from individuals with neuromuscular disease. Researchers want to better understand the disease progression and ultimately improve the care and survival of those with neuromuscular disease.

Subjects’ participation is expected to last for the duration of the study, which is continuous.

Current Multiple Sclerosis (MS) enrolling studies with a brief description:

Study and Contact Information

ARPEGGIO (sponsored by TEVA Pharmaceuticals)

Protocol #: TV5600-CNS-20006

Principal Investigator: Jill Conway, MD

Coordinator: Megan Kramer – 704-446-0803


The purpose of this study is to find out whether treatment with laquinimod is safe and effective in reducing the loss of brain volume and reducing MS worsening. Patients with PPMS may experience a reduction in their brain volume over time, and reduction in the size of the brain is thought to be related to worsening of MS.

Laquinimod is a new oral drug that is being developed for the treatment of MS and other indications. It is “investigational” because it has not been approved by regulatory authorities, such as the Food and Drug. This is the first study that evaluates laquinimod in patients with PPMS.

Potentially eligible participants must be between ages 25 and 55, inclusive; have a confirmed diagnosis of PPMS; show disease progression in the previous 2 years and have an EDSS limited to patients with an EDSS score of 3.0 to 5.5, inclusive. Approximately 375 patients will take part in the study at 120 sites in the U.S., Canada and Europe, including 3-5 patients at CMC-Neurology. Participation is due to last 18-30 months.


Protocol #:

Principal Investigator: Donna Graves, MD

Coordinator: Joyce Pitner – 704-446-1349


The goal of this study is to assess the efficacy of the drug BG00012 in delaying disability progression in subjects with secondary progressive multiple sclerosis (SPMS) who are progressing independent of relapses. The drug is currently marketed for the treatment of relapsing MS. This is the first trial to measure the effectiveness of BG00012 in people with SPMS.

Subjects will be randomized to receive either BG00012 or placebo (which looks like the BG00012 capsule but does not have any active ingredient). Each person will have a 50-50 chance of being placed into either group. Both groups will taking one 240-mg capsule twice daily.

Individuals with SPMS may be eligible for the study if they are between 18 to 58 years old, inclusive; experienced the onset of SPMS at least 2 years before; have documented, confirmed evidence of disease progression independent of clinical relapses over the previous year; have an EDSS score of 3.0 to 6.5, inclusive; have an MS Severity Score (MSSS) of 4 or higher.

Study participation will last for 108 weeks.


About Carolinas HealthCare System
Who We Are
Community Benefit
Corporate Financial Information
Diversity & Inclusion
Annual Report
Patient Links
Pay Your Bill
Hospital Pre-Registration
Patient Rights
Financial Assistance
Quality & Value Reports
Join Carolinas HealthCare System
Physician Careers

For Employees
Carolinas Connect
Connect with Us
Watch Carolinas HealthCare on YoutubeFollow Carolinas HealthCare on TwitterLike Carolinas HealthCare on FacebookContact Carolinas HealthCareJoin Carolinas HealthCare on LinkedInGo to our mobile website.